JP5411709B2 - 痛みおよび炎症の処置のためのヒ素化合物の使用 - Google Patents

痛みおよび炎症の処置のためのヒ素化合物の使用 Download PDF

Info

Publication number
JP5411709B2
JP5411709B2 JP2009548463A JP2009548463A JP5411709B2 JP 5411709 B2 JP5411709 B2 JP 5411709B2 JP 2009548463 A JP2009548463 A JP 2009548463A JP 2009548463 A JP2009548463 A JP 2009548463A JP 5411709 B2 JP5411709 B2 JP 5411709B2
Authority
JP
Japan
Prior art keywords
pain
meta arsenite
sodium meta
disease
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009548463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518022A (ja
Inventor
ウォン，マイケル
ヤン，ヨン−ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PANAPHIX Inc
Original Assignee
PANAPHIX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PANAPHIX Inc filed Critical PANAPHIX Inc
Publication of JP2010518022A publication Critical patent/JP2010518022A/ja
Application granted granted Critical
Publication of JP5411709B2 publication Critical patent/JP5411709B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
JP2009548463A 2007-02-02 2008-02-01 痛みおよび炎症の処置のためのヒ素化合物の使用 Expired - Fee Related JP5411709B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89900707P 2007-02-02 2007-02-02
US60/899,007 2007-02-02
US12/068,006 US8945505B2 (en) 2007-02-02 2008-01-31 Use of arsenic compounds for treatment of pain and inflammation
US12/068,006 2008-01-31
PCT/US2008/052751 WO2008097824A2 (en) 2007-02-02 2008-02-01 Use of arsenic compounds for treatment of pain and inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013097681A Division JP5825611B2 (ja) 2007-02-02 2013-05-07 痛みおよび炎症の処置のためのヒ素化合物の使用

Publications (2)

Publication Number Publication Date
JP2010518022A JP2010518022A (ja) 2010-05-27
JP5411709B2 true JP5411709B2 (ja) 2014-02-12

Family

ID=39322911

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009548463A Expired - Fee Related JP5411709B2 (ja) 2007-02-02 2008-02-01 痛みおよび炎症の処置のためのヒ素化合物の使用
JP2013097681A Expired - Fee Related JP5825611B2 (ja) 2007-02-02 2013-05-07 痛みおよび炎症の処置のためのヒ素化合物の使用
JP2014209816A Expired - Fee Related JP5853347B2 (ja) 2007-02-02 2014-10-14 痛みおよび炎症の処置のためのヒ素化合物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013097681A Expired - Fee Related JP5825611B2 (ja) 2007-02-02 2013-05-07 痛みおよび炎症の処置のためのヒ素化合物の使用
JP2014209816A Expired - Fee Related JP5853347B2 (ja) 2007-02-02 2014-10-14 痛みおよび炎症の処置のためのヒ素化合物の使用

Country Status (18)

Country Link
US (2) US8945505B2 (enExample)
EP (1) EP2114419B8 (enExample)
JP (3) JP5411709B2 (enExample)
KR (1) KR101479519B1 (enExample)
CN (2) CN103550253A (enExample)
AR (1) AR065138A1 (enExample)
AU (1) AU2008214084C9 (enExample)
BR (1) BRPI0807154B8 (enExample)
CA (3) CA2845292C (enExample)
DK (1) DK2114419T3 (enExample)
ES (1) ES2460868T3 (enExample)
IL (3) IL200173A (enExample)
MX (1) MX2009008174A (enExample)
NZ (1) NZ578621A (enExample)
PL (1) PL2114419T3 (enExample)
RU (3) RU2630574C2 (enExample)
TW (1) TWI404538B (enExample)
WO (1) WO2008097824A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090061022A1 (en) * 2004-10-08 2009-03-05 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8045505B2 (en) * 2007-01-18 2011-10-25 Science Applications International Corporation Mechanism for automatic network formation and medium access coordination
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
EP2432480B1 (en) * 2009-05-18 2021-05-05 The University of Hong Kong Compositions and methods for treating inflammatory arthritis
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
PT2475362T (pt) * 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
KR101834366B1 (ko) * 2016-11-21 2018-03-05 주식회사 케마스 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
CN106890353A (zh) * 2017-03-31 2017-06-27 应剑波 一种具有抗菌滋养功能的医用辅料
US10716807B2 (en) * 2017-05-09 2020-07-21 Medsenic Method of treating relapsing-remitting multiple sclerosis using arsenic trioxide
MA52088A (fr) * 2018-03-22 2021-01-27 Komipharm Int Australia Pty Ltd Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication
RU2687599C1 (ru) * 2018-11-22 2019-05-15 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения постмастэктомического синдрома
CN109674817B (zh) * 2019-01-31 2021-06-29 哈尔滨医科大学 三氧化二砷在制备治疗晚期动脉粥样硬化药物中的用途
CN117085038A (zh) * 2019-05-21 2023-11-21 麦德赛尼克公司 金属离子增强砷的治疗作用的用途
CN115243692A (zh) * 2020-02-16 2022-10-25 科微范国际澳大利亚私人有限公司 使用偏亚砷酸盐的治疗方法
RU2755329C2 (ru) * 2020-03-13 2021-09-15 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ /ФГБУ "РНЦРХТ им. академика А.М. Гранова" Минздрава России Способ лечения нерезектабельной гилюсной холангиокарциномы
WO2021198535A1 (en) * 2020-04-03 2021-10-07 Medsenic Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
EP3988093A1 (en) * 2020-10-22 2022-04-27 Medsenic Use of an arsenic compound for treating a cytokine storm
KR102240693B1 (ko) * 2020-05-18 2021-04-15 주식회사 케마스 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
CA3205138A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536273A (en) * 1895-03-26 Tavus rein
US1498639A (en) * 1919-12-02 1924-06-24 David S Pratt Arsenical composition and method of making same
US3622664A (en) * 1968-11-21 1971-11-23 John A Brown Treatment of infectious keratitis in animals with sodium arsenite
SU955909A1 (ru) * 1980-06-25 1982-09-07 Центральный Ордена Ленина Институт Усовершенствования Врачей Способ профилактики осложнений при пересадке тканей
US4677974A (en) * 1985-09-30 1987-07-07 David Leonardi Method and apparatus for immobilizing an eyelid
CA2051012C (en) 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
US5889048A (en) 1994-02-18 1999-03-30 Vorobieva; Tamara Vasilievna Methods and compositions for treating defective cell functions
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
IT1272994B (it) * 1994-05-25 1997-07-01 Giampiero Valletta Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.-
IT1295067B1 (it) * 1997-09-25 1999-04-27 Walter Tarello Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale
DE69840057D1 (de) 1997-10-15 2008-11-06 Polarx Biopharmaceuticals Inc Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von Krebs des zentralen Nervensystems
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI259079B (en) * 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
EP2042182B1 (en) 2002-04-10 2013-05-22 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
RU2310460C2 (ru) * 2002-04-10 2007-11-20 Корея Микробиолоджикал Лабораторис, Лтд. Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
JP2005206591A (ja) * 2003-12-25 2005-08-04 Mitsubishi Pharma Corp 神経因性疼痛の予防及び／又は治療のための医薬
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
JP2006206461A (ja) 2005-01-26 2006-08-10 Teizo Chinen アレルギー疾患の予防・治療用組成物
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases

Also Published As

Publication number Publication date
AU2008214084B2 (en) 2013-10-31
CA2677388A1 (en) 2008-08-14
DK2114419T3 (da) 2014-06-10
CA2845299A1 (en) 2008-08-14
AU2008214084C9 (en) 2014-04-03
BRPI0807154A2 (pt) 2014-04-22
IL200173A0 (en) 2010-04-15
BRPI0807154B1 (pt) 2021-01-12
CN101641105A (zh) 2010-02-03
MX2009008174A (es) 2009-11-26
JP2010518022A (ja) 2010-05-27
IL217891A (en) 2014-05-28
JP2015007138A (ja) 2015-01-15
US10058570B2 (en) 2018-08-28
RU2012134218A (ru) 2014-02-20
NZ578621A (en) 2011-06-30
IL200173A (en) 2013-12-31
IL229255A0 (en) 2013-12-31
US20130309319A1 (en) 2013-11-21
CN103550253A (zh) 2014-02-05
US20080193560A1 (en) 2008-08-14
IL229255A (en) 2015-02-26
CA2845292C (en) 2017-09-12
BRPI0807154B8 (pt) 2021-05-25
KR20090122348A (ko) 2009-11-27
AR065138A1 (es) 2009-05-20
HK1138512A1 (en) 2010-08-27
RU2013151904A (ru) 2015-05-27
RU2009132951A (ru) 2011-03-10
AU2008214084A1 (en) 2008-08-14
JP2013147511A (ja) 2013-08-01
RU2468806C2 (ru) 2012-12-10
EP2114419A2 (en) 2009-11-11
ES2460868T3 (es) 2014-05-14
IL217891A0 (en) 2012-03-29
TW200843734A (en) 2008-11-16
PL2114419T3 (pl) 2014-10-31
CA2845299C (en) 2017-03-07
WO2008097824A3 (en) 2009-03-26
EP2114419B1 (en) 2014-04-09
CA2677388C (en) 2017-07-25
RU2665362C2 (ru) 2018-08-29
JP5853347B2 (ja) 2016-02-09
AU2008214084C1 (en) 2014-03-06
JP5825611B2 (ja) 2015-12-02
WO2008097824A2 (en) 2008-08-14
KR101479519B1 (ko) 2015-01-08
EP2114419B8 (en) 2014-06-11
RU2630574C2 (ru) 2017-09-11
TWI404538B (zh) 2013-08-11
US8945505B2 (en) 2015-02-03
CA2845292A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
JP5411709B2 (ja) 痛みおよび炎症の処置のためのヒ素化合物の使用
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
IL194987A (en) Use of PIF peptide to produce a drug to regulate the immune system
Tavares et al. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies
EP2753931A1 (en) Autoimmune and inflammatory disorder therapy
EP3256124B1 (en) Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis
CA3154792A1 (en) Compositions and methods for treating idiopathic pulmonary fibrosis
WO2019079759A1 (en) ANTI-PERSISTENCE AND ANTI-VIRULENCE COMPOUNDS WITH BROAD SPECTRUM
HK1138512B (en) Sodium meta arsenite for use in the treatment of pain and inflammation
WO2006046528A1 (ja) 糸球体疾患治療剤
Femi-Olabisi et al. Safety Evaluation of Ethanolic Extract of Parquetina nigrescens Leaves (Afzel.) on Selected Tissues in Letrozole-induced Polycystic Ovarian Syndrome Rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131108

R150 Certificate of patent or registration of utility model

Ref document number: 5411709

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees